8 patents
Utility
Quinazolinones, Pharmaceutical Compositions Containing the Same, and Methods of Using the Same
2 Nov 23
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof.
Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Alexander PERRYMAN, Sheldon N. CRANE, Vouy Linh TRUONG, Abbas ABDOLI, Alexanne BOUCHARD
Filed: 27 Apr 23
Utility
Methods of Using MYT1 Inhibitors
25 May 23
Disclosed are methods of using inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1), e.g., in the treatment of subjects in need thereof.
Daniel DUROCHER, Jordan YOUNG, Frank SICHERI, Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Frédéric VALLÉE, Alexander PERRYMAN, Jean-François TRUCHON, Robert PAPP, Theresa ZHANG, Artur VELOSO, Jimmy FOURTOUNIS, Patrick BEAULIEU
Filed: 1 Apr 21
Utility
Compounds, Pharmaceutical Compositions, and Methods of Preparing Compounds and of Their Use
18 May 23
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof.
Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Frédéric VALLÉE, Alexander PERRYMAN, Jean-François TRUCHON, Robert PAPP, Patrick BEAULIEU
Filed: 1 Apr 21
Utility
Tricyclic Heteroarenes, Pharmaceutical Compositions Containing the Same, and Methods of Using the Same
11 May 23
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof.
Janek SZYCHOWSKI, Evelyne DIETRICH, Frédéric VALLÉE
Filed: 6 Oct 22
Utility
Compounds, Pharmaceutical Compositions, and Methods of Preparing Compounds and of Their Use
20 Apr 23
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof.
Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Frédéric VALLÉE, Alexander PERRYMAN, Jean-François TRUCHON, Robert PAPP, Patrick BEAULIEU, Vouy Linh TRUONG, Kaveh MATINKHOO, Sheldon N. CRANE
Filed: 4 Oct 22
Utility
Substituted 2-MORPHOLINOPYRIDINE Derivatives As Atr Kinase Inhibitors
16 Jun 22
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof.
Sheldon N. Crane, Vouy-linh Truong, Abbas Abdoli, Jean-François Truchon, Cameron Black, Stéphane Dorich, Lee Fader, Stéphanie Lanoix, Paul Jones, Miguel St-Onge, Audrey Picard, Cyrus M. Lacbay
Filed: 20 Jan 22
Utility
Compounds, Pharmaceutical Compositions, and Methods of Preparing Compounds and of Their Use As Atr Kinase Inhibitors
9 Sep 21
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof.
Sheldon N. CRANE, Vouy Linh TRUONG, Abbas ABDOLI, Jean-François TRUCHON, Cameron BLACK, Stéphane DORICH, Lee FADER, Stéphanie LANOIX, Paul JONES, Miguel ST-ONGE, Audrey PICARD, Cyrus M. LACBAY
Filed: 30 Apr 21
Utility
Use of Atr Inhibitors In Combination with Parp Inhibitors
17 Jun 21
Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer.
Michal ZIMMERMANN, Anne ROULSTON, Maria KOEHLER
Filed: 11 Dec 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first